Company overview
Informed Genomics is a UK-based genomic testing laboratory providing innovative cancer testing services and accredited solutions to both NHS and private sector clients. The company delivers comprehensive genomic profiling and variant interpretation services to support precision oncology and clinical decision-making. Their offerings include automated workflows for data analysis, variant calling, and identification of relevant clinical trials to enhance diagnostic accuracy and treatment planning.
Cancer Genomic Testing for NHS & Private is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include cancer genomic testing, comprehensive genomic profiling, precision oncology, variant interpretation, nhs genomic services.
Structured facts
- Website
- https://informedgenomics.com
- Markets served
- United States & Americas
- Keywords
- cancer genomic testing, comprehensive genomic profiling, precision oncology, variant interpretation, nhs genomic services
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What types of genomic testing does Informed Genomics provide?
- Informed Genomics specializes in cancer genomic testing services, including comprehensive genomic profiling (CGP) assays for oncology. Their services encompass data analysis, variant calling, interpretation, and identification of relevant clinical trials to inform treatment decisions.
- Which healthcare sectors does Informed Genomics serve?
- Informed Genomics provides accredited solutions to both the NHS (National Health Service) and the private healthcare sector in the UK, delivering services that support precision medicine and improve patient care outcomes.
- What regulatory recognition has Informed Genomics received?
- Informed Genomics was highly commended in May 2024 for Delivering Innovation in Health and Care, demonstrating recognition for their innovative approach to cancer testing services and healthcare solutions.
Related editorial coverage
- FDA Companion Diagnostic Policies: Market Evolution in Precision Oncology
- Next-Generation Sequencing MEA: Impact on Precision Oncology Treatment Selection
- AACR 2026: ctDNA, Immunotherapy, and KRAS Target Breakthroughs
Explore lab tools and QA/QC resources for R&D teams.
